NVS Stock Recent News

Basel, March 31, 2025 – Novartis announced today the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. She will continue to report to Vas Narasimhan, M.D., CEO of Novartis and remain on the Executive Committee of Novartis (ECN). Klaus Moosmayer, currently Chief Ethics, Risk & Compliance Officer of Novartis, has decided to leave the company and will step down from the ECN to pursue his next chapter of leadership outside Novartis. The current Ethics Risk & Compliance (ERC) function will move under the leadership of Karen Hale. “Klaus has been integral to building trust with society by solving our legacy compliance topics and putting an ethics, risk and compliance system in place, which is regarded highly internally and externally. The impact he has had on our company, our people and our reputation will be long-lasting,” said Vas Narasimhan, CEO of Novartis. “I want to thank Klaus for his extraordinary lead

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI) and now before chemotherapy Pluvicto significantly reduced risk of progression or death by 59% and more than doubled median radiographic progression-free survival ( rPFS) vs.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Industry Description

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.

Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G1-3 C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney failure2-4 Novartis continues to advance multiple kidney disease treatments with high unmet need, compounding capabilities and strengthening unique leadership presence EAST HANOVER, N.J. , March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition1-4.

Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)